A Revolution in the Treatment of Obesity - 25/09/24
Abstract |
Forty percent of Americans are obese and 20% are overweight. Until recently, notwithstanding great efforts to combat this chronic, worsening epidemic, the only therapy that “worked” was surgery. However, recently, a new class of safe drugs (incretins) have been developed that cause obese patients to lose ∼20 to 25% of their body weight. Herein we recount this revolution and its implications.
Le texte complet de cet article est disponible en PDF.Keywords : Agonists, GIP, GLP-1, Glucagon, Incretins, Insulin, Semaglutide, Tirzepatide
| Funding: This review had no funding. |
|
| Conflicts of Interest: None. |
|
| Authorship: The sole author is responsible for all content: Writing – original draft, review & editing, Formal analysis, Conceptualization. |
Vol 137 - N° 10
P. 925-928 - octobre 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

